Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients
Pm. Battezzati et al., Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients, ALIM PHARM, 15(9), 2001, pp. 1427-1434
Background: Combined medical treatment may provide further benefit to prima
ry biliary cirrhosis (PBC) patients administered ursodeoxycholic acid (UDCA
).
Aim: To evaluate the long-term effects of colchicine and UDCA in symptomati
c PBC patients.
Patients/methods: We extended up to 10 years the double-blind treatment of
44 symptomatic PBC patients originally included in a 3-year multicentre stu
dy comparing UDCA and colchicine (U + C) versus UDCA and placebo (U + P). O
utcome measures were death or liver transplantation; incidence of clinicall
y relevant events; clinical and quantitative variables retaining prognostic
information.
Results: Mean follow-up was 7 +/- 3 years. One patient was lost, three with
drew because of jaundice (U + P); two patients stopped colchicine but remai
ned on UDCA. Eleven patients (two for liver-unrelated reasons, U + P) and s
ix patients (U + C) died, three and two patients, respectively, were transp
lanted (incidence rate difference, five cases per 100 patient-years; 95% CI
, -1 to 11). Hepatocellular carcinoma developed in one (U + P) and four (U
+ C) patients (difference, -2; CI, -5 to 1), portal hypertension complicati
ons in nine patients from each group (difference, 1; CI, -5 to 6). Trends o
f serum bilirubin, Mayo score, antipyrine clearance were similar among trea
tment groups.
Conclusions: In cirrhotic PBC patients, colchicine does not offer additiona
l benefits to UDCA. In this population, UDCA does not obviate disease progr
ession.